410 related articles for article (PubMed ID: 24443923)
41. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
[TBL] [Abstract][Full Text] [Related]
42. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety.
Di Donato V; Schiavi MC; Iacobelli V; D'oria O; Kontopantelis E; Simoncini T; Muzii L; Benedetti Panici P
Maturitas; 2019 Mar; 121():93-100. PubMed ID: 30509754
[TBL] [Abstract][Full Text] [Related]
43. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
44. Long-term use of ospemifene in clinical practice for vulvo-vaginal atrophy: end results at 12 months of follow-up.
Pingarrón Santofímia C; Lafuente González P; Guitiérrez Vélez MDC; Calvente Aguilar V; Poyo Torcal S; Terol Sánchez P; Palacios S
Gynecol Endocrinol; 2022 Jul; 38(7):577-582. PubMed ID: 35670533
[TBL] [Abstract][Full Text] [Related]
45. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause.
Unkila M; Kari S; Yatkin E; Lammintausta R
J Steroid Biochem Mol Biol; 2013 Nov; 138():107-15. PubMed ID: 23665515
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
47. Ospemifene in clinical practice for vulvo-vaginal atrophy: results at 3 months of follow-up of use.
Pingarron C; de Lafuente P; Ierullo AM; Poyo Torcal S; Maroto Díaz CJ; Palacios S
Gynecol Endocrinol; 2021 Jun; 37(6):562-566. PubMed ID: 33300371
[TBL] [Abstract][Full Text] [Related]
48. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.
Pinkerton JV; Bushmakin AG; Komm BS; Abraham L
Maturitas; 2017 Jun; 100():57-63. PubMed ID: 28539177
[TBL] [Abstract][Full Text] [Related]
49. Genitourinary Syndrome of Menopause.
Shifren JL
Clin Obstet Gynecol; 2018 Sep; 61(3):508-516. PubMed ID: 29787390
[TBL] [Abstract][Full Text] [Related]
50. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications.
Kangas L; Unkila M
Steroids; 2013 Dec; 78(12-13):1273-80. PubMed ID: 24055829
[TBL] [Abstract][Full Text] [Related]
51. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
[TBL] [Abstract][Full Text] [Related]
52. Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause.
Archer DF; Simon JA; Portman DJ; Goldstein SR; Goldstein I
Expert Rev Endocrinol Metab; 2019 Sep; 14(5):301-314. PubMed ID: 31526199
[No Abstract] [Full Text] [Related]
53. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Archer DF; Labrie F; Bouchard C; Portman DJ; Koltun W; Cusan L; Labrie C; Côté I; Lavoie L; Martel C; Balser J;
Menopause; 2015 Sep; 22(9):950-63. PubMed ID: 25734980
[TBL] [Abstract][Full Text] [Related]
54. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.
Labrie F; Derogatis L; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
J Sex Med; 2015 Dec; 12(12):2401-12. PubMed ID: 26597311
[TBL] [Abstract][Full Text] [Related]
55. Structure of Epithelial and Stromal Compartments of Vulvar and Vaginal Tissue From Women With Vulvo-Vaginal Atrophy Taking Ospemifene.
Alvisi S; Baldassarre M; Gava G; Mancini I; Gagliardi M; Seracchioli R; Meriggiola MC
J Sex Med; 2018 Dec; 15(12):1776-1784. PubMed ID: 30446472
[TBL] [Abstract][Full Text] [Related]
56. Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women.
Tucker KM; Godha K; Mirkin S; Archer DF
Menopause; 2018 Jul; 25(7):762-766. PubMed ID: 29509598
[TBL] [Abstract][Full Text] [Related]
57. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
58. Ospemifene, vulvovaginal atrophy, and breast cancer.
Wurz GT; Soe LH; DeGregorio MW
Maturitas; 2013 Mar; 74(3):220-5. PubMed ID: 23332519
[TBL] [Abstract][Full Text] [Related]
59. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Labrie F; Archer DF; Bouchard C; Girard G; Ayotte N; Gallagher JC; Cusan L; Baron M; Blouin F; Waldbaum AS; Koltun W; Portman DJ; Côté I; Lavoie L; Beauregard A; Labrie C; Martel C; Balser J; Moyneur É;
Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
[TBL] [Abstract][Full Text] [Related]
60. Ospemifene efficacy and safety data in women with vulvovaginal atrophy.
Pup LD; Sánchez-Borrego R
Gynecol Endocrinol; 2020 Jul; 36(7):569-577. PubMed ID: 32329400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
